/
Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above and in Item 1A. Risk Factors to be a complete statement of all potential risks and uncertainties.
$17.85
$0.19 (-1.05%)
EOD Jul 17, 2026
13.05% operating margin is respectable but not wide. ROIC at 14.77%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue grew 8.0%, steady but not accelerating.
At 48x earnings, the current multiple leaves limited room for execution misses or growth deceleration. Net debt of $2.41B represents 8.9x FCF, leverage limits flexibility.
48.2x earnings, 24.4x FCF. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$3.05B
▲ +8.0% YoY
Net Income (TTM)
$122M
▲ +161.6% YoY
Op. Margin
14.30%
▲ +4.1pp YoY
ROIC
17.38%
▲ +5.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$241M
▲ +11.0% YoY
Op. Cash Flow (TTM)
$306M
▲ +15.2% YoY
Net Debt
$2.37B
Cash & Equiv.
$198M
5Y CAGR: +8.7%
5Y CAGR: -3.5%
Continue Research
At a P/E of 48.2 and a price-to-free-cash-flow of 24.4, Amneal Pharmaceuticals (AMRX) trades above a two-stage DCF intrinsic value of about $7.45 per share, so at $17.85 the stock looks overvalued (58.2% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Amneal Pharmaceuticals scores 65/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $7.45 per share for AMRX, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $5.59. At today's $17.85, that puts the stock about 58.2% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Amneal Pharmaceuticals scores 65 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 14.3% operating margin and a 17.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. AMRX currently trades above its estimated intrinsic value and scores 65/100 on quality (solid). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.